绝经后血清BMP-7、OCN水平与骨质疏松的相关性研究

目的探究骨形态发生蛋白-7(BMP-7)、骨钙素(OCN)在绝经后骨质疏松(OP)患者血清中的水平与骨代谢指标骨特异性碱性磷酸酶(BAP)、I型胶原交联氨基末端肽(NTX)及骨密度(BMD)的相关性。方法选取2017年5月至2019年3月收治的93例绝经女性OP患者作为OP组;并以同期来我院进行健康体检的86例绝经女性作为对照组进行研究;以实时荧光定量PCR(qRT-PCR)法检测两组受试者血清BMP-7、OCN表达水平;以酶联免疫吸附法(ELISA)检测两组受试者血清BAP、NTX水平,计算BAP/NTX比值;利用双能X线骨密度仪测定两组受试者骨密度;分析OP患者血清BMP-7、OCN表达水平与骨代谢相关指标、BMD的相关性及BMP-7表达水平与OCN的关系; Logistic回归分析OP发生的影响因素。结果 OP组患者雌二醇水平、血清BMP-7、OCN、BAP/NTX、BMD水平均明显低于对照组(t=11.962、9.969、12.823、4.052、18.215,P均0.05); OP组患者血清BAP、NTX水平均明显高于对照组(t=4.014、9.092,P均0.05); OP患者血清BMP-7、OCN表达水平与BAP、NTX均呈负相关(P均0.05),与BAP/NTX、BMD均呈正相关(P均0.05),BMP-7表达水平与OCN呈正相关(P 0.05);雌二醇、BMD是影响OP发生的保护险因素(95%CI=0.536～0.978、0.335～0.916,P均0.05),BAP、NTX是影响OP发生的危险因素(95%CI=1.336～1.859、1.427～2.357,P均0.05)。结论绝经女性血清BMP-7、OCN表达水平下调,BMP-7、OCN与骨代谢指标及BMD密切相关,两者可能与BAP、NTX、BMD相互影响,从而在OP发展进程中发挥作用。     

Evaluation of serum level of Osteocalcin hormone in male infertility

The suggested concept of “bone as an endocrine organ” had shed the light on the role of osteocalcin, an osteoblast secreted hormone, in regulation of testosterone production. This study aimed to assess the association between the active undercarboxylated form of osteocalcin (ucOC) and semen parameters and hormonal levels in infertile male patients. The study was carried on 34 infertile male patients and 20 fertile healthy control males. Semen analysis and serum level of testosterone, LH and FSH were performed in addition to serum level of ucOC in cases and controls. The results revealed significant differences between cases and controls in all measured semen and hormonal parameters. In addition, significant higher level of ucOC in cases than control group (p = .019). On the other hand, ucOC was not related significantly to any of the measured hormones or semen parameters. There was no significant correlation between ucOC and sperm concentration, total motility, morphology (p = .594, .640, .940 respectively) and similarly between ucOC and testosterone level or LH level (p = .275, .954 respectively). The significant higher level of ucOC in infertile cases cannot be used as a predictor of male reproductive parameters.     

Adenotonsillectomy outcomes regarding bone age and osteocalcin in treatment of obstructive sleep apnea syndrome in children

Background:To investigate the effect of adenotonsillec tomy (AT) on bone development,quality of life and polysomnography evaluation in children with obstructive sleep apnea syndrome (OSA).Methods:Preoperative and postoperative (6 months) physical examination,PSG,bone age (BA) and osteocalcin (OC) evaluation were performed on the selected OSA children (n=92) and the healthy children (n=87).The OSA children were also scored based on the OSA 18-item questionnaire.A two-year follow-up was conducted to evaluate BA and OC changes.Results:After AT,81 (88.04％) OSA children recovered completely,eight (8.70％) achieved remarkable improvements,and three (3.26％) achieved moderate improvements.In the OSA children,postoperative OSA 18-item score and the scores of the five domains were significantly higher than preoperative ones.Compared with the preoperative,body mass index (BMI),weight for age Z-sores,height for age Z-sores,weight for height Z-sores and BMI Z-score in the OSA group 6 months after the operation were significantly increased,but no significant difference was detected between the OSA and the control group.The changes of BA and chronological age in the OSA group were significantly different from those in the control group.Two years after AT,BA between the two groups was no longer significantly different.Preoperative serum OC in the OSA group was lower than that in the control group,but increased to normal levels 6 months after AT.Correlation analysis showed serum OC levels were negatively correlated with apnea hyponea index,obstructive apnea index,arousal index,and lowest oxygen saturation.Conclusions:After AT,bone growth and development in children with OSA recovered gradually,and the serum OC levels decreased to the normal level.Therefore,preventive measures and positive treatments should be applied to minimize the negative effects of OSA in children.     

骨代谢标志物与骨密度预测经皮穿刺椎体成形术后椎体再骨折的价值

目的探讨椎体骨密度及骨代谢标志物在老年骨质疏松性胸腰椎骨折经皮穿刺椎体成形术（percutaneous vertebro plasty, PVP）后预测椎体再骨折发生的价值。方法采用回顾性分析方法收集2018年1月—2019年1月在同济大学附属第十人民医院接受椎体成形术治疗的老年骨质疏松性胸腰椎压缩性骨折患者50例,其中术后12个月相邻椎体再骨折23例（经影像学证实）,根据相邻椎体是否再次骨折分为骨折组和未骨折组。采用双能X线骨密度仪测定并记录患者术前及术后6、12个月病椎相邻椎体和髋部骨密度,酶联免疫吸附法（ELISA）进行血清骨钙素N端中分子片段（N-terminal middle molecular fragment of osteocalcin, N-MID）和25羟维生素D[25 hydroxyvitamin D, 25(OH)D]检测。结果未骨折组强化椎体的相邻椎体骨密度(bone mineral density, BMD)在术后6、12个月降低（P=0.000）,组内两两比较术前至术后12个月BMD持续降低,降低率分别为7.80%和18.50%(P=0.000);术后6、12个月再骨折组髋部BMD低于未骨折组(P<0.001,P=0.000);再骨折组血清N-MID和25(OH)D浓度均低于未骨折组(P=0.000),Logistic回归分析显示再骨折的发生与血清N-MID浓度呈负相关(P=0.033),与25(OH)D的浓度呈负相关(P=0.031)。结论PVP术后相邻椎体和髋部BMD、N-MID、25(OH)D降低的老年骨质疏松患者容易发生相邻椎体的再骨折。     

普伐他汀对去势大鼠骨质疏松症的治疗作用

目的 探讨普伐他汀片对去势大鼠骨质疏松症的治疗作用,为临床用药提供依据.方法 取12周龄的雌性Wistar大鼠加只,氯氨酮(5 mg/100 g)麻醉条件下,其中30只打开腹腔去除双侧卵巢,逐层缝合,另10只予以单纯打开腹腔不切除卵巢.将大鼠分模型组、普伐他汀组、阳性对照组、正常对照假手术组4组,饲养12周后,分别予以生理盐水(10 ml/kg)、普伐他汀水溶液(2 ms/ks)、α-D3水溶液(0.05μg/kg)及生理盐水(10 ml/kg)灌胃.灌胃12周后,活杀各组动物,以双能X线密度测定仪测定骨密度.取血清用放免法测定血清中骨钙素(BGP)、降钙素(CT).通过三点弯曲试验,记录载荷-变形曲线,测定骨生物力学指标.结果 经过12周的普伐他汀水溶液灌胃治疗,明显提高了去势大鼠的骨密度、血清激素水平,与模型组比较,差异均有统计学意义(P<0.01或<0.05),并能改善治疗组大鼠的骨力学性能.结论 普伐他汀可提高去势大鼠的骨密度值及血清激素水平,改善骨的生物力学性能,具有治疗骨质疏松症的作用.     

骨碎补总黄酮对牙周炎大鼠龈沟液骨钙素及牙槽骨骨密度的影响

目的：观察骨碎补总黄酮对牙周炎大鼠龈沟液骨钙素（OC）和牙槽骨骨密度的影响,探讨其治疗牙周炎的机制。方法成功建立 SD 大鼠牙周炎模型之后,使用完全随机分组方法将大鼠分为正常组、牙周炎组、骨碎补总黄酮组,每组18只。建模4周后分别灌服生理盐水和骨碎补总黄酮240 mg／（kg·d）。各组大鼠分别在建模后第4,6,8周各处死6只。放射免疫分析法测定龈沟液 OC 水平,显微 CT 测定大鼠牙槽骨骨密度。结果牙周炎组龈沟液 OC 水平显著高于正常组和骨碎补总黄酮组（P ＜0．05）;骨碎补总黄酮组龈沟液 OC 水平在6周和8周时显著低于牙周炎组（P ＜0．05）,8周时与正常组龈沟液 OC 水平相比差异无统计学意义（P ＞0．05）。牙周炎组牙槽骨骨密度显著低于正常组和骨碎补总黄酮组（P ＜0．05）;骨碎补总黄酮组牙槽骨骨密度在 6 和8周时显著高于牙周炎组（P ＜0．05）。结论骨碎补总黄酮可降低牙周炎大鼠龈沟液骨钙素水平,增加牙槽骨骨密度,对大鼠牙周炎具有一定治疗作用。     

血液透析患者血清骨钙素的变化及其意义

骨钙素(BGP)是反映骨代谢的一项特异性的生化指标.为了解BGP在尿毒症血液透析患者的变化,我们测定了43例维持性血液透析患者的血清BGP,并探讨其意义.     

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report

Rationale:Tumor-induced osteomalacia (TIO) is curable by tumor resection, but detection of the tumor can be challenging. Overproduction of fibroblast growth factor 23 (FGF23) by the tumor causes hypophosphatemia and consequently induces inappropriate bone turnover. Conventionally oral phosphate supplementation was the only treatment for TIO, but had risks of hypercalciuria and nephrocalcinosis. Burosumab, a human monoclonal anti-FGF23 antibody, was recently post-marketed in Japan against for FGF23-related hypophosphatemia. Herein, we present a case of TIO with undetectable tumor that was successfully treated with burosumab.Patient concerns:A 47-year-old woman was forced to use a wheelchair because of pain in both feet.Diagnosis:Laboratory findings showed hypophosphatemia, elevated bone markers, and high serum FGF23 without renal tubular defects. Imaging studies revealed bone atrophy in the feet, decreased bone density, and multiple pseudofractures in the talar, sacral, and L5 vertebral regions. After excluding drug-induced and hereditary osteomalacia, we diagnosed her as TIO.Interventions:Comprehensive imaging studies and stepwise venous sampling failed to localize the tumor, and we started to administer subcutaneous burosumab.Outcomes:After administration of burosumab, her serum phosphate was normalized without phosphate supplementation within 2 months. Improvement of pseudofractures, relief of pain evaluated by a visual analog scale, and normalization of bone biomarkers were observed. The patient was able to stand by herself after 6 months administration of burosumab.Lessons:This is the first report in clinical practice to demonstrate favorable effects of burosumab, including not only normalization of serum phosphate but also improvements of pseudofractures and subjective pain, in a patient with TIO and undetectable tumor.     

A proposal for standardizing urine collections for bone resorption markers measurement

Diurnal variations in the excretion of bone resorption markers were assessed in order to identify the type of urine collection which provides the most information on bone resorption rate and its relation to measuring bone dynamics in a postmenopausal population. Sixty women, ages 43–67 and without disease or treatment known to affect bone mineral density, were divided into two groups on the basis of femoral mineral density T-score: <1.5 (Group I), >1.5 (Group II). Bone formation was assessed by measuring bone alkaline phosphatase activity and osteocalcin concentration, bone resorption by urinary hydroxyproline, pyridinoline and deoxypiridinoline, N-telopeptide, galactosyl hydroxylysine, and CrossLaps. To identify the more appropriate collection times, urine samples were collected from 7 am to 3 pm; from 3 pm to 11 pm; from 11 pm to 7 am. Twenty-four hour urine collection and first morning void urine samples were also measured. The findings suggest that nocturnal collection and first morning void samples provide the most reliable data on the rate of bone degradation, possibly showing bone loss not only in osteopenic patients but also in women with a low T-score. Nocturnal and first morning samples should therefore be recommended in order to standardize sample collection, as they enable an accurate assessment of bone resorption markers and improved comparability to results from different studies, as well as a less cumbersome collection modality. J. Clin. Lab. Anal. 12:145–149, 1998. © 1998 Wiley-Liss, Inc.